Serum fetuin-A and RANKL levels in patients with early stage breast cancer

Background: Breast cancer (BC) is the primary cause of mortality due to cancer in females around the world. Fetuin-A is known to increase metastases over signals and peroxisomes related with growing. Receptor activator of nuclear factor-kB ligand (RANKL) takes part in cell adhesion, and RANKL inhibition is used in the management of cancer. We aimed to examine the relationship between serum fetuin-A, RANKL levels, other laboratory parameters and clinical findings in women diagnosed with early stage BC, in our population. Methods: Women having early stage BC (n=117) met our study inclusion criteria as they had no any anti-cancer therapy before. Thirty-seven healthy women controls were also confirmed with breast examination and ultrasonography and/or mammography according to their ages. Serum samples were stored at -80 °C and analysed via ELISA. Results: Median age of the patients was 53 (range: 57-86) while it was 47 (range: 23-74) in the healthy group. Patients had lower high-density lipoprotein levels (p=0.002) and higher neutrophil counts (p=0.014). Fetuin-A and RANKL levels did not differ between the groups (p=0.116 and p=0.439, respectively) but RANKL leves were found to be lower in the favorable histological subtypes (p=0.04). Conclusions: In this study, we found no correlation between serum fetuin-A levels and clinical findings in patients diagnosed with early stage BC. However, RANKL levels are found to be lower in subgroups with favorable histopathologic subtypes such as tubular, papillary and mucinous BC and there was statistically significant difference

Original Article Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung

Abstract: Aim: Non-small cell lung carcinoma is the leading cause of cancer related to death in the world. Squamous cell lung carcinoma (SqCLC) is the second most frequent histological subtype of lung carcinomas. Recently, growth factors, growth factor receptors, and signal transduction system-related gene amplifications and mutations are extensively under investigation to estimate the prognosis and to develop individualized therapies in SqCLC. In this study, besides the signal transduction molecule phosphatidyl inositol-3-phosphate kinase (IP3K) p110α, we explored the expressions of fibroblast growth factor 2 (FGF2) and receptor-1 (FGFR1) in tumor tissue and also their clinical and prognostic significance in patients with early/advanced SqCLC. Materials and methods: From 2005 to 2013, 129 patients (23 early, 106 advanced disease) with a histopathological SqCLC diagnosis were selected from the hospital files of Cukurova University Medical Faculty for this study. Two independent pathologists evaluated FGFR1, FGF2, and PI3K (p110α) expressions in both tumor and stromal tissues from 99 of the patients with sufficient tissue samples, using immunohistochemistry. Considering survival analysis separately for patients with both early and advanced stage diseases, the relationship between the clinical features of the patients and expressions were evaluated by univariate and multivariate analyses. Results: FGFR1 expression was found to be low in 59 (60%) patients and high in 40 (40%) patients. For FGF2; 12 (12%) patients had high, 87 (88%) patients had low expression and for IP3K; 31 (32%) patients had high and 66 (68%) patients had low expressions. In univariate analysis, overall survival (OS) was significantly associated with stage of the disease and the performance status of the patient (P<0.0001 and P<0.001). There was no significant difference in OS of the patients with either low or high expressions of FGFR1, FGF2, and IP3K. When the patients with early or advanced stage disease were separately taken into consideration, the relationship did not differ, either. Any of FGFR1, FGF2 or IP3K expressions was not found predictive for the treatment of early or advanced staged patients. On the other hand, the expressions of both FGFR1 and FGF2 were significantly different with respect to smoking, scar of tuberculosis and scar of radiotherapy (P=0.002; P=0.06 and P=0.05, respectively). Discussion: There has not been identified an effective individualized treatment for SqCLC yet. Therefore, in order to be able to develop such a treatment in the future, it is essential to identify the genetic abnormalities that are responsible for the biological behaviors and carcinogenesis of SqCLC. Although we could not show the prognostic and predictive significance of FGFR1, FGF2 and IP3K expressions in SqCLC, we determined the expression rates of FGFR1, FGF2 and IP3K as a reference for Turkish patients. In conclusion, we want to put some emphasis on the fact that, pulmonary fibrosis which is a late complication of radiotherapy at stage III disease, and the scar of tuberculosis could be associated with FGFR1 and FGF2 expressions

Serum IL-17 levels can be diagnostic for gastric cancer.

Purpose: Gastric cancer (GC) is one of the most common malignancies worldwide. Although it has been strongly associated with immunopathology, IL-17 also has an important role in host defense so this makes it more important in GC, which is a microorganism-related cancer. The aim of this study was to determine the clinical significance of the serum levels of IL-17 in GC patients

IMMUNE MARKERS IN SURGICALLY RESECTED EARLY STAGE NON-SMALL CELL LUNG CANCER PATIENTS

Purpose: Non-small cell lung cancer (NSCLC) is the most common cancer and the leading cause of cancer-related deaths worldwide. Inflammatory markers, such as C-reactive protein (CRP), neutrophil-lymphocyte ratio (NLR), lymphocyte-monocyte ratio and platelet-lymphocyte ratio (PLR), serve as indexes for the immune status of the host and the degree of tumor progression. In this study, we evaluated NLR and PLR values in early stage lung cancer patients before and after surgery and its correlation with clinical variables and survival

Primary Spinal Glioblastoma Multiforme: A Case Report and Review of The Literature

WOS: 000343369600017Introduction: Primary spinal glioblastoma multiforme is a very rare disease with high morbidity and mortality rates. No definite treatment algorhythm can be constituted, but multimodal treatment regimens have been administered. Aim of the treatment is to excise the mass nearly completely, and then application of radiotherapy and chemotherapy in a short period. Methods: Publications were identified by browsing search engines such as PubMed and MEDLINE for English-language articles since 1989 using a list of keywords; as well as identifying references from review articles. The following keywords were used for searching databases: primary, spinal, glioblastoma multiforme. Results: Intramedullary mass was detected at the levels of C2-T8 in the spinal magnetic resonance imaging (MRI) examination performed in our 4-year old male patient, who applied to us with complaints of weakness in lower extremities and gaita-urine incontinence. Sepsis was developed in postoperative period of the patient, whose mass was gross-totally resected by using microsurgery method. After the patient was started to have radiotherapy, he was extubated with improvements in the clinical state and neurological picture. He has been followed up at the hospital in the three-month monitorization after the treatment. Literature data suggested that all three therapy modalities can be used for sGBM, sequentially or concurrently, it has a poor survival, most of the patients die due to disease and the duration of symptoms are very short. Conclusion: Because the disease is very rare, prospective studies cannot be performed in this patient population

Sorafenib in the treatment of metastatic paraganglioma: A case report.

48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- JUN 01-06, 2012 -- Chicago, ILWOS: 000318009802321…Amer Soc Clin Onco

ROLE OF INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) AND INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-3 (IGFBP-3) IN THE DIAGNOSIS OF PANCREATIC ADENOCARCINOMA AND MONITORING TREATMENT RESPONSE

Purpose: Pancreatic cancer occurs rarely in humans, and it is one of the most fatal five cancer types with very poor prognosis. Early diagnosis of pancreatic cancer is difficult due to late presentation of symptoms. The purpose of our study was to evaluate the utility of IGFBP-3 and IGF-1 in early diagnosis of pancreatic cancer and in monitoring treatment response and contribute to the studies conducted in this regard

Nonalcoholic fatty liver disease after adjuvant therapy in nonmetastatic breast cancer.

Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 31-JUN 04, 2013 -- Chicago, ILWOS: 000335419603070…Amer Soc Clin Onco

THE EFFECT OF PRETREATMENT NEUTROPHIL/LEUCOCYTE RATIO ON SURVIVAL IN PATIENTS WITH LOCALLY ADVANCED ESOPHAGEAL CANCER RECEIVING CHEMORADIOTHERAPY

Introduction: Esophageal cancer (EC) is a highly lethal malignancy. The majority of esophageal cancers are squamous cell or adenocarcinomas. Although the incidence of squamous cell carcinoma (SCC) is decreasing in the United States, the incidence of adenocarcinoma arising out of Barrett's esophagus is rising dramatically, although less so in the last few years. Treatment in locally advanced EC (LA-EC) must be multidisciplinary. There are only few factors which affects the prognosis. Our aim was to investigate the prognostic and predictive roles of pretreatment neutrophil/leucocyte (neu/leu) ratios in LA-EC patients receiving chemoradiotherapy (CRT)